论文部分内容阅读
本文报道小剂量干扰素与胸腺肽联合对慢性乙肝20例抗病毒效应的追踪观察结果,并与同期同批同剂量单纯干扰素治疗13例慢性乙肝作对照,追踪时间均为治后半年—2年,从HBeAg、HBcAg、DNAP、HBV DNA阴转率来看,治疗组分别为58.8％、60％、60％及66.6％、对照组分别为50％、50％、100％及50％。再从HBV四项复制指标改变来看,则治疗组4例全阴转,7例仅一项阳性,总有效率达61.1％(11/18),而对照组仅为20％(2/10),P<0.01,认为干扰素与胸腺肽联合治疗优于对照组,并扼要讨论增强干扰素抗病毒效应的各种措施,认为干扰素与胸腺肽联合,不论从前已报道近期疗效和本文远期追踪来看均较安全而有效,二者合用起到增强抗病毒效应的作用,值得进一步探索。
This article reports the small dose of interferon and thymosin in 20 cases of chronic hepatitis B antiviral effect of the follow-up observation and the same period with the same batch of the same dose of interferon alone in the treatment of 13 cases of chronic hepatitis B as control, followed up for 6 months - 2 years From the HBeAg, HBcAg, DNAP and HBV DNA negative rates, the treatment groups were 58.8%, 60%, 60% and 66.6% respectively, while the control group was 50%, 50%, 100% and 50% respectively. And then from the four indicators of HBV replication change point of view, then the treatment group 4 cases of all-yin, 7 cases only one positive, the total effective rate was 61.1% (11/18), while the control group was only 20% (2/10 ), P <0.01, that the combination of interferon and thymosin better than the control group, and summarize the various measures to enhance the antiviral effect of interferon that interferon and thymosin in combination, whether previously reported short-term efficacy and long-term follow-up It is safer and more effective to combine these two functions to enhance the antiviral effect and worth further exploration.